SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 3, 2012
Avanir Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (949) 389-6700
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 8.01. Other Events.
On December 3, 2012, Avanir Pharmaceuticals, Inc. (the Company or Avanir) received a Markman claim construction ruling by Judge Leonard P. Stark of the United States District Court for the District of Delaware (the Court) in Avanirs ongoing patent infringement case against Actavis South Atlantic LLC, Actavis Inc., Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc., Impax Laboratories, Inc., Wockhardt, Ltd., Wockhardt USA, LLC, Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc. (collectively, the Defendants).
In a Markman ruling, the court determines the meaning of disputed patent terms at issue in patent litigation. Judge Starks ruling construed five terms in the patents asserted by Avanir in the litigation. After comprehensive briefing and oral argument, Judge Stark issued an order adopting Avanirs proposed or stipulated patent term constructions.
Avanir filed suit against the Defendants in response to Abbreviated New Drug Applications (ANDAs) filed by the Defendants seeking to market and sell generic versions of the currently approved dose of NUEDEXTA® prior to the expiration of U.S. patents 7,659,282, 8,227,484 and RE38,115. Avanir filed the lawsuits on the basis that the Defendants proposed generic products infringe certain patents held by Avanir.
Although the parties intend to vigorously defend and enforce their patent rights, Avanir cannot predict timing or outcome of this action. Any adverse outcome in the litigation described above could adversely impact Avanir and its revenues.
A copy of the Courts ruling in the Markman hearing is filed herewith as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.